C0074493_interactsWith_C0608826 | Knowledge4COVID-19

Property	Value
?:effect	<https://research.tib.eu/covid-19/entity/C0001688>
?:hasPrimarySource	<https://research.tib.eu/covid-19/SourceName/UMLS>
?:impact	increase
?:interaction	The risk or severity of adverse effects can be increased when Sibutramine is combined with Aceprometazine.
?:objectDrug	<https://research.tib.eu/covid-19/entity/C0608826>
?:object_hasDrugBankID	<https://research.tib.eu/covid-19/entity/DB01615>
?:precipitantDrug	<https://research.tib.eu/covid-19/entity/C0074493>
?:precipitant_hasDrugBankID	<https://research.tib.eu/covid-19/entity/DB01105>
is ?:subClassOf of	<https://research.tib.eu/covid-19/entity/C0074493_hasPharmacodynamic_C0608826>
?:type	<https://research.tib.eu/covid-19/vocab/DrugDrugInteraction>

Metadata

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>	<https://research.tib.eu/covid-19/data/entity/DB00959_interactsWith_DB09102>
<http://purl.org/net/provenance/ns#createdBy>	Anon_1

expand all